Biocryst Pharmaceuticals (BCRX) Liabilities from Discontinued Operations (2025)

Biocryst Pharmaceuticals (BCRX) reported Liabilities from Discontinued Operations of 436000.0 for Q3 2025, down 3.96% quarter-over-quarter from 454000.0 in Q2 2025.

Biocryst Pharmaceuticals (BCRX) Liabilities from Discontinued Operations (2025) Analysis & Trends

Biocryst Pharmaceuticals has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 436000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Biocryst Pharmaceuticals 2.02 Bn 1.78 Bn 151.04 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 436,000.00
Sep 30, 2025 436,000.00
Jun 30, 2025 454,000.00
Jun 30, 2025 454,000.00